Horizon Pharma PLC Company Profile (NASDAQ:HZNP)

About Horizon Pharma PLC (NASDAQ:HZNP)

Horizon Pharma PLC logoHorizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:HZNP
  • CUSIP: 44047T10
  • Web: www.horizonpharma.com
Capitalization:
  • Market Cap: $2.26 billion
  • Outstanding Shares: 163,354,000
Average Prices:
  • 50 Day Moving Avg: $13.17
  • 200 Day Moving Avg: $12.66
  • 52 Week Range: $9.45 - $21.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 11.09
  • P/E Growth: 1.02
Sales & Book Value:
  • Annual Revenue: $1.03 billion
  • Price / Sales: 2.20
  • Book Value: $6.30 per share
  • Price / Book: 2.20
Profitability:
  • EBITDA: ($46,520,000.00)
  • Net Margins: -42.40%
  • Return on Equity: 22.85%
  • Return on Assets: 6.86%
Debt:
  • Debt-to-Equity Ratio: 1.83%
  • Current Ratio: 1.61%
  • Quick Ratio: 1.46%
Misc:
  • Average Volume: 3.43 million shs.
  • Beta: 1.5
  • Short Ratio: 5.78
 

Frequently Asked Questions for Horizon Pharma PLC (NASDAQ:HZNP)

What is Horizon Pharma PLC's stock symbol?

Horizon Pharma PLC trades on the NASDAQ under the ticker symbol "HZNP."

How will Horizon Pharma PLC's stock buyback program work?

Horizon Pharma PLC announced that its Board of Directors has initiated a stock repurchase plan on Sunday, June 4th 2017, which allows the company to buyback 1,000% of shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its stock is undervalued.

How were Horizon Pharma PLC's earnings last quarter?

Horizon Pharma PLC (NASDAQ:HZNP) posted its earnings results on Monday, August, 7th. The company reported $0.41 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.12 by $0.29. The firm earned $289.51 million during the quarter, compared to analyst estimates of $237.01 million. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The firm's revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the business posted $0.56 EPS. View Horizon Pharma PLC's Earnings History.

When will Horizon Pharma PLC make its next earnings announcement?

Horizon Pharma PLC is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Horizon Pharma PLC.

Where is Horizon Pharma PLC's stock going? Where will Horizon Pharma PLC's stock price be in 2017?

11 brokerages have issued 1 year target prices for Horizon Pharma PLC's stock. Their forecasts range from $12.00 to $30.00. On average, they expect Horizon Pharma PLC's stock price to reach $18.18 in the next year. View Analyst Ratings for Horizon Pharma PLC.

What are analysts saying about Horizon Pharma PLC stock?

Here are some recent quotes from research analysts about Horizon Pharma PLC stock:

  • 1. According to Zacks Investment Research, "Horizon has been focused on expanding its orphan drug business.The company has been quite active on the acquisition front over the past few quarters. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. Moreover, in Jun 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in the Europe, the Middle East and Africa regions to Chiesi Farmaceutici S.p.A. as the company focuses on higher-return businesses. Shares of the company have underperformed the industry. With the company’s efforts to expand Actimmune’s label suffered a setback, focus will be on Krystexxa’s performance. Stiff competition for drugs will also impact sales." (10/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "We are maintaining our Overweight rating and $17, 12 month PT for HZNP shares, but lowering our 2017 and 2018 EPS estimates because we have taken out some sales for the Raptor franchise now that Horizon has completed the sale of its EU marketing rights to Chiesi (Not Covered). We continue to expect Krystexxa sales to be impacted by the 340b program in 4Q17, which could prove conservative. Please see our note for details Potential HHS Delay Could Be Positive for HZNP’s Krystexxa Sales This Year. We expect orphan drug sales to increase 50% YOY which is in line with Horizon’s guidance, and rheumatology sales to increase 37% YOY, which is also roughly in line with Horizon’s guidance. Valuation. We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $17." (9/11/2017)
  • 3. Piper Jaffray Companies analysts commented, "We had the opportunity to travel with Horizon senior management in meetings with investors. We gained additional insight into Pennsaid 2% and Ravicti, and also came away with insights into management's latest thinking regarding M&A. Though there are undoubtedly some headwinds facing the primary care segment, we believe that this segment should be on largely stable footing over the long-term given HZNP's payer contracting efforts. That dynamic combined with continued strength from the rare disease segment points to a long-term EPS CAGR (2017-2022) in the mid-teens, and should translate into multiple expansion with a 2017E P/E currently at 7x. We reiterate our Overweight rating and are lowering our PT to $30 from $32 (see below for more details)." (3/24/2017)
  • 4. Guggenheim analysts commented, "HZNP reported a 4Q16 beat, underscoring our confidence that HZNP can continue to meet or exceed earnings expectations in '17+. Post 4Q16, we think that the peak sales potential of Pennsaid 2%, Procysbi, and Krystexxa are underappreciated, with additional earnings upside potentially coming from M&A as HZNP redeploys cash generated by its Primary Care ("PC") business into business development focused on orphan and rare disease indication medicines. While concerns remain over growth prospects for HZNP's PC business, Ravicti and Actimmune, these assets continue to generate meaningful cash to fuel HZNP's growth aspiration of $2B in sales by 2020." (2/27/2017)
  • 5. Mizuho analysts commented, "We are positive on HZNP ahead of the February 27 earnings call: We think the company may deliver a 4Q:16 earnings beat. We model 4Q:16 revenues of $325.4M and EPS of $0.57 relative to consensus $308.5M and $0.50 and implied guidance $309-$314M. Horizon has delivered strong beats in the past and we expect adjusted EBITDA to approach the higher end of the guidance range of $450-$460M. With respect to 2017 guidance, we fall below FactSet consensus estimates of $1,289.7M and $2.39 (we model $1,281.8M and $2.29), but note that Horizon may be able to beat this range via a combination of both price and volume growth, so guidance could come in stronger than expected. There is still significant uncertainty around business operation under the new PBM contracts, gross to net discounts, infrastructure needs, and the timing of anticipated volume growth. We therefore expect the focus of the call to be around these issues as well as on future business development targets and pipeline outlook." (2/22/2017)

Who are some of Horizon Pharma PLC's key competitors?

Who are Horizon Pharma PLC's key executives?

Horizon Pharma PLC's management team includes the folowing people:

  • Timothy P. Walbert, Chairman of the Board, President, Chief Executive Officer
  • Paul W. Hoelscher, Chief Financial Officer, Executive Vice President
  • Barry J. Moze, Executive Vice President, Chief Administrative Officer
  • Brian K. Beeler, Executive Vice President, General Counsel
  • Robert F. Carey, Executive Vice President, Chief Business Officer
  • Michael A. DesJardin, Executive Vice President - Technical Operations
  • George P. Hampton, Executive Vice President - Primary Care Business Unit
  • David A. Happel, Executive Vice President - Orphan Business Unit
  • Jeffrey W. Sherman M.D., Executive Vice President - Research and Development and Chief Medical Officer
  • Vikram Karnani, Senior Vice President - Rheumatology Business Unit

Who owns Horizon Pharma PLC stock?

Horizon Pharma PLC's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Nationwide Fund Advisors (0.06%) and Fox Run Management L.L.C. (0.01%). Company insiders that own Horizon Pharma PLC stock include Jeffrey W Sherman, Michael G Grey, Robert Carey and Virinder Nohria. View Institutional Ownership Trends for Horizon Pharma PLC.

Who sold Horizon Pharma PLC stock? Who is selling Horizon Pharma PLC stock?

Horizon Pharma PLC's stock was sold by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors and Fox Run Management L.L.C.. View Insider Buying and Selling for Horizon Pharma PLC.

How do I buy Horizon Pharma PLC stock?

Shares of Horizon Pharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Horizon Pharma PLC's stock price today?

One share of Horizon Pharma PLC stock can currently be purchased for approximately $13.86.


MarketBeat Community Rating for Horizon Pharma PLC (NASDAQ HZNP)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  519 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  713
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Horizon Pharma PLC (NASDAQ:HZNP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $18.18 (31.18% upside)
Consensus Price Target History for Horizon Pharma PLC (NASDAQ:HZNP)
Price Target History for Horizon Pharma PLC (NASDAQ:HZNP)
Analysts' Ratings History for Horizon Pharma PLC (NASDAQ:HZNP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/22/2017Stifel NicolausReiterated RatingBuy$20.00N/AView Rating Details
10/15/2017Piper Jaffray CompaniesSet Price TargetBuy$18.00N/AView Rating Details
10/5/2017Jefferies Group LLCReiterated RatingBuy$16.00N/AView Rating Details
9/28/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
9/28/2017Goldman Sachs Group, Inc. (The)Initiated CoverageBuy -> Buy$16.00MediumView Rating Details
9/26/2017Cantor FitzgeraldReiterated RatingBuy$17.00LowView Rating Details
8/28/2017MizuhoReiterated RatingHold$9.00 -> $12.00MediumView Rating Details
8/10/2017BMO Capital MarketsReiterated RatingOutperform$17.00 -> $18.00HighView Rating Details
5/9/2017Citigroup Inc.Lower Price TargetBuy$20.00 -> $13.00MediumView Rating Details
2/28/2017Morgan StanleyReiterated RatingEqual Weight$20.00N/AView Rating Details
2/27/2017GuggenheimInitiated CoverageBuy$30.00N/AView Rating Details
9/12/2016Brean CapitalReiterated RatingBuy$32.00N/AView Rating Details
11/11/2015WallachBeth CapitalUpgradeBuyN/AView Rating Details
(Data available from 10/24/2015 forward)

Earnings

Earnings History for Horizon Pharma PLC (NASDAQ:HZNP)
Earnings by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Earnings History by Quarter for Horizon Pharma PLC (NASDAQ HZNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017$0.22N/AView Earnings Details
8/7/2017Q2 2017$0.12$0.41$237.01 million$289.51 millionViewListenView Earnings Details
5/8/2017Q1 2017$0.25$0.21$248.71 million$220.90 millionViewListenView Earnings Details
2/27/2017Q416$0.51$0.64$307.93 million$310.30 millionViewListenView Earnings Details
11/7/2016Q316$0.63$0.70$270.04 million$273.70 millionViewListenView Earnings Details
8/8/2016Q216$0.50$0.62$235.43 million$257.40 millionViewN/AView Earnings Details
5/9/2016Q116$0.30$0.34$197.73 million$204.70 millionViewN/AView Earnings Details
2/29/2016Q415$0.62$0.63$240.92 million$244.50 millionViewListenView Earnings Details
11/6/2015Q315$0.41$0.59$185.70 million$292.70 millionViewListenView Earnings Details
8/7/2015Q215$0.32$0.39$156.41 million$172.80 millionViewListenView Earnings Details
5/8/2015Q115$0.22$0.16$104.20 million$113.10 millionViewN/AView Earnings Details
2/27/2015Q414$0.23$0.27$95.50 million$103.80 millionViewN/AView Earnings Details
11/6/2014Q314$0.19$0.24$73.17 million$75.10 millionViewN/AView Earnings Details
8/7/2014Q214$0.16$0.14$58.35 million$66.10 millionViewN/AView Earnings Details
5/9/2014Q114$0.01$0.10$42.69 million$51.90 millionViewN/AView Earnings Details
3/13/2014Q413($0.08)($0.22)$32.20 million$43.10 millionViewN/AView Earnings Details
11/8/2013Q3 13($0.25)($0.03)$18.31 million$31.50 millionViewN/AView Earnings Details
8/9/2013Q213($0.32)($0.24)$16.09 million$17.64 millionViewN/AView Earnings Details
5/10/2013Q113($0.35)($0.30)$9.47 million$9.20 millionViewN/AView Earnings Details
11/13/2012Q312($0.68)($0.39)$4.12 million$7.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Horizon Pharma PLC (NASDAQ:HZNP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171$0.10$0.10$0.10
Q3 20171$0.19$0.19$0.19
Q4 20171$0.17$0.17$0.17
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Horizon Pharma PLC (NASDAQ:HZNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Horizon Pharma PLC (NASDAQ:HZNP)
Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 82.32%
Insider Trades by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Insider Trades by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2017Michael G GreyDirectorBuy10,000$9.48$94,800.00View SEC Filing  
3/1/2017Robert CareyEVPSell31,808$16.03$509,882.24View SEC Filing  
8/2/2016Jeffrey W. ShermanEVPSell2,900$20.00$58,000.00View SEC Filing  
6/15/2016Virinder NohriaDirectorSell25,000$17.69$442,250.00View SEC Filing  
2/26/2016Jeffrey W ShermanEVPSell4,100$20.00$82,000.00View SEC Filing  
12/10/2015Jeffrey W ShermanEVPSell4,456$20.00$89,120.00View SEC Filing  
9/21/2015Jeffrey W ShermanEVPSell7,750$31.78$246,295.00View SEC Filing  
7/15/2015Jeffrey W ShermanEVPSell26,887$35.55$955,832.85View SEC Filing  
3/13/2015Jeff HimawanDirectorSell554,564$22.44$12,444,416.16View SEC Filing  
3/10/2015Jeff HimawanDirectorSell1,614,827$21.85$35,283,969.95View SEC Filing  
11/19/2014Jeff HimawanDirectorSell3,450,000$12.05$41,572,500.00View SEC Filing  
11/19/2014Jeffrey W ShermanEVPSell24,999$12.05$301,237.95View SEC Filing  
11/19/2014Timothy P WalbertCEOSell150,000$12.05$1,807,500.00View SEC Filing  
11/13/2014Balaji VenkataramanMajor ShareholderSell6,086,957$11.54$70,243,483.78View SEC Filing  
11/13/2014Virinder NohriaDirectorSell1,739,130$11.54$20,069,560.20View SEC Filing  
9/30/2014Vaere Robert J DeCFOSell51,942$12.28$637,847.76View SEC Filing  
5/19/2014Timothy WalbertCEOSell31,742$12.94$410,741.48View SEC Filing  
5/19/2014Todd SmithEVPSell10,159$12.94$131,457.46View SEC Filing  
5/19/2014Vaere Robert DeCFOSell12,939$12.94$167,430.66View SEC Filing  
12/13/2013Jeffrey BirdDirectorBuy668,673$6.50$4,346,374.50View SEC Filing  
12/9/2013Timothy WalbertCEOSell12,124$6.79$82,321.96View SEC Filing  
12/9/2013Todd SmithEVPSell11,322$6.91$78,235.02View SEC Filing  
11/21/2013Jeffrey BirdDirectorBuy151,089$6.24$942,795.36View SEC Filing  
9/25/2012Jeffrey W BirdDirectorBuy575,356$3.49$2,007,992.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Horizon Pharma PLC (NASDAQ:HZNP)
Latest Headlines for Horizon Pharma PLC (NASDAQ:HZNP)
Source:
Loading headlines, please wait.

Social

Chart

Horizon Pharma PLC (HZNP) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.